Achieve Life Sciences Inc (F:SP4P) — Market Cap & Net Worth
Market Cap & Net Worth: Achieve Life Sciences Inc (SP4P)
Achieve Life Sciences Inc (F:SP4P) has a market capitalization of $191.64 Million (€163.92 Million) as of May 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #16704 globally and #1578 in its home market, demonstrating a 2.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Achieve Life Sciences Inc's stock price €3.60 by its total outstanding shares 53233988 (53.23 Million). Analyse SP4P cash flow conversion to see how efficiently the company converts income to cash.
Achieve Life Sciences Inc Market Cap History: 2015 to 2026
Achieve Life Sciences Inc's market capitalization history from 2015 to 2026. Data shows change from $145.00 Billion to $224.05 Million (-49.21% CAGR).
Achieve Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Achieve Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13632.44x
Achieve Life Sciences Inc's market cap is 13632.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $69.01 Billion | $5.06 Million | -$20.13 Million | 13632.44x | N/A |
Competitor Companies of SP4P by Market Capitalization
Companies near Achieve Life Sciences Inc in the global market cap rankings as of May 3, 2026.
Key companies related to Achieve Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Achieve Life Sciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Achieve Life Sciences Inc's market cap moved from $145.00 Billion to $ 224.05 Million, with a yearly change of -49.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €224.05 Million | -2.70% |
| 2025 | €230.27 Million | +3.79% |
| 2024 | €221.87 Million | -3.65% |
| 2023 | €230.27 Million | +57.31% |
| 2022 | €146.38 Million | -64.36% |
| 2021 | €410.76 Million | +4.76% |
| 2020 | €392.09 Million | -36.99% |
| 2019 | €622.24 Million | -51.47% |
| 2018 | €1.28 Billion | -92.23% |
| 2017 | €16.51 Billion | -76.08% |
| 2016 | €69.01 Billion | -52.41% |
| 2015 | €145.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Achieve Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $191.64 Million USD |
| MoneyControl | $191.64 Million USD |
| MarketWatch | $191.64 Million USD |
| marketcap.company | $191.64 Million USD |
| Reuters | $191.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sop… Read more